30Mar
28Mar
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease
Neuraly, a clinical-stage biotechnology company pioneering development of disease-modifying agents for neurodegenerative disorders, today announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD). The primary endpoint, change from baseline to Week 36 in the sum of MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Examination) after 36 weeks of NLY01 treatment, compared to placebo, did not reach statistical significance. NLY01 was safe and well tolerated. The effect was...
28Mar
Immusoft Acquires Exclusive, Worldwide Rights to Intellectual Property for Genome Edited Primary B Cells from the University of Minnesot
Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for compositions of matter and methods to make and use genome edited primary B cells. The parent patent application is titled, “Genome Edited Primary B cell and Methods of Making and Using.” The IP includes proprietary methods that...
24Mar
Aras Named a Leader in Product Lifecycle Management by Independent Research Firm
Aras, a provider of the most powerful low-code platform with applications to design, build and operate complex products, today announced that it has been named a leader in The Forrester Wave™: Product Lifecycle Management For Discrete Manufacturers, Q1 2023 evaluation. Forrester noted that ""Aras appeals to manufacturers with a strong interest in exploiting a low-code platform for their own specific approach to managing the digital thread, from as-designed to as-manufactured and as-maintained."" According to the Forrester report, "Aras' superior performance,...
24Mar
Candidly Wins “Best Student Loan Management Platform” Designation in 7th Annual FinTech Breakthrough Awards Program
Candidly, the market’s leading student debt management platform, today announced that it is the winner of the “Best Student Loan Management Platform” award in the 7th annual FinTech Breakthrough Awards program conducted by FinTech Breakthrough. This is the second consecutive year that Candidly has been recognized with a FinTech Breakthrough Award. Read more >>
21Mar
Wasabi CFO On Doing Business With SVB: What Worked, What Didn’t And What’s Ahead
Silicon Valley Bank: The Right Bank, But Wasabi Ready To Move On. The surprise demise of Silicon Valley Bank (SVB) has left much of the tech startup business concerned. Those clients primarily were tech startups that depended on SVB for loans, virtual currency business and financing acquisitions. One of those SVB companies was Boston-based cloud storage technology developer Wasabi, which had banked with SVB for years. Wasabi was fortunate in that it was already making plans to take advantage of...
14Mar
Myomo Reports Fourth Quarter and Full Year 2022 Financial Result
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022. inancial and operational highlights for the fourth quarter of 2022 include the following: Product and total revenues were $4.0 million, up 2% sequentially and similar to the prior year quarter; Revenue units were 101, up 16% sequentially and down 6% compared with the prior year...
08Mar
Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd. Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. AKS-452 has completed a Phase II/III clinical trial in India, with data showing robust safety profile and a 91% seroconversion rate at Day 56. Akston is now working with a...
08Mar
Candidly picks up student debt relief where new US policies leave off
While some fintech companies have taken the borrower approach, others are looking at it from an employee benefit perspective and attracting interest from venture capital investors. Those include Goodly, Highway Benefits, which announced $3.1 million in seed funding last week, and Candidly, which announced $20.5 million in Series B funding today. Read more >>
07Mar